CLINICAL STUDIES ON BRL 28500 (CLAVULANIC ACID-TICARCILLIN)

BRL 28500, a formulation of ticarcillin (TIPC, 15 parts) and clavulanic acid (CVA, 1 part) was evaluated for clinical efficacy in 20 patients suffering from pneumonia (8), chronic bronchitis (2), acute cystitis (1), chronic cystitis (4), acute pyelitis (3) and chronic pyelitis (2). The clinical resp...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 34; no. Supplement4; pp. 371 - 378
Main Authors YOSHIDA, SHUICHIRO, YONETA, MASASHI, TAMURA, TOYOICHI, YASHIRO, HITOSHI, FUKUCHI, KAZUHIKO, SAGARA, MORIO, KASHIWAMURA, HIDEAKI, TAKEBE, KAZUO, OKAMOTO, KATSUHIRO, NAKAMURA, TERUO, BABA, MASAYUKI
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1986
公益社団法人 日本化学療法学会
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.34.Supplement4_371

Cover

More Information
Summary:BRL 28500, a formulation of ticarcillin (TIPC, 15 parts) and clavulanic acid (CVA, 1 part) was evaluated for clinical efficacy in 20 patients suffering from pneumonia (8), chronic bronchitis (2), acute cystitis (1), chronic cystitis (4), acute pyelitis (3) and chronic pyelitis (2). The clinical response was excellent in 7 patients, good in 12 and poor in 1. All strains of bacteria were eradicated following the administration of BRL 28500 including 3 that were considered ticarcillin-resistant. Against 2 of these resistant strains the MIC of BRL 28500 was determined. One strain (K. Oxytoca) was sensitive to BRL 28500 although the other strain (P.aeruginosa) appeared resistant. There were no side effects. Laboratory abnormalities were limited to a slight elevation of GOT, GPT, LDH and γ-GTP in 1 case.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.34.Supplement4_371